BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis (MBT)
Pivotal Study to Evaluate the Efficacy and Safety of the BreathID® System for Detection of Cirrhosis Using the ¹³C-methacetin Breath Test(MBT)
Sponsor: Meridian Bioscience, Inc.
A PHASE3 clinical study on Chronic Liver Disease, this trial is completed. The trial is conducted by Meridian Bioscience, Inc. and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2021 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Meridian Bioscience, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .